Although limited by use of a KIR ligand-ligand model, a study of haplo-HCT with PTCy for various hematologic malignancies found that KIR-ligand mismatch was associated with a lower incidence of relapse and better PFS for patients transplanted in relapse but had no significant impact on those transplanted in CR (149). The gene discussed is KIR3DL1; the disease is hematologic disorder.